Financial Analysis: Entrada Therapeutics (TRDA) vs. Its Peers

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Entrada Therapeutics to related companies based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, risk and institutional ownership.

Analyst Recommendations

This is a summary of current ratings for Entrada Therapeutics and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics 1 2 4 0 2.43
Entrada Therapeutics Competitors 9959 15361 45766 1602 2.54

Entrada Therapeutics presently has a consensus target price of $16.75, indicating a potential upside of 285.06%. As a group, “Biotechnology” companies have a potential upside of 114.65%. Given Entrada Therapeutics’ higher possible upside, equities analysts clearly believe Entrada Therapeutics is more favorable than its competitors.

Volatility & Risk

Entrada Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Entrada Therapeutics’ competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Valuation and Earnings

This table compares Entrada Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Entrada Therapeutics $3.98 million -$143.75 million -1.13
Entrada Therapeutics Competitors $746.10 million $10.34 million -17.98

Entrada Therapeutics’ competitors have higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Entrada Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entrada Therapeutics -4,057.98% -64.00% -50.49%
Entrada Therapeutics Competitors -12,519.20% -215.47% -31.42%

Summary

Entrada Therapeutics competitors beat Entrada Therapeutics on 7 of the 13 factors compared.

Entrada Therapeutics Company Profile

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.